The IHC staining of tumor sections suggested that ProAgio treatment decreased Hif-1a in lung tumors (Figure 4B,C), suggesting that, similar to our observations with pancreatic and breast cancer, ProAgio treatment decreased lung cancer hypoxia due to its anti-angiogenic effects. This evidence concerns the gene HIF1A and breast cancer.